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At Risk for Huntington's Disease
HD is a genetically caused brain disorder that causes uncontrollable bodily movements and robs
people's ability to walk, talk, eat, and think. The final result is a slow, ugly death. Children of parents
with HD have a 50-50 chance of inheriting the disease. There is no cure or treatment.
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FRIDAY, JUNE 27, 2014

New California stem cell chief stresses speed and
efficiency in search for treatments
A major hope of those facing Huntington's disease (and numerous other
diseases) resides in stem cell research.
The new president and CEO of the California Institute for Regenerative
Medicine (CIRM), transferring from the pharmaceutical industry, has
assumed the helm of the $3 billion organization stressing efficiency,
including a pledge to prioritize speedier development of treatments for the
many diseases falling within the agency’s scope.
“What I promise I will do is to bring stem cell therapies and treatments to
the patients that need them,” C. Randal Mills, Ph.D., chosen to run CIRM
by its board of directors on April 30, said in San Diego on June 24 at the
third of three “Meet the New CIRM President” events. “That is quite
sincerely what I have done my entire career, and the only thing I care
about and the only reason I came to CIRM.”
Dr. Mills was introduced by CIRM board chair Jonathan Thomas, J.D.,
Ph.D. The meeting took place in conjunction with the 2014 BIO
International Convention, June 23-26, which showcased the work of
leading biotech firms and featured a keynote speech by British business
magnate Sir Richard Branson and a moderated Q & A with former
Secretary of State and potential 2016 presidential candidate Hillary
Rodham Clinton. The convention attracted more than 15,000 participants
from all 50 states and 70 countries.
Dr. Mills outlined four questions he said will guide him in decision-making
at CIRM.
First, he said, "is whatever we're doing speeding up a treatment reaching a
patient?"
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Secondly, will CIRM’s activities increase the likelihood of a treatment
reaching a patient? There are many “valleys of death,” or dead ends, in
stem cell research, Dr. Mills noted.
Third, is CIRM meeting an unmet medical need, as opposed to a condition
already successfully dealt with by other medical means?
Fourth, is CIRM doing all this efficiently?
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Randy Mills speaks to disease advocates and stem cell industry representatives in
San Diego (photo by Gene Veritas).
Taking care of patients
Dr. Mills said his patient-oriented outlook started during his
undergraduate studies in microbiology and cell studies at the University of
Florida, in Gainesville.
“During that time I worked as a medic in the emergency room,” he told the
audience. “I saw and dealt with a lot of patients and got a pretty good sense
of what patient care was like and delivery was like.”
Dr. Mills obtained his Ph.D. in drug development, also at the University of
Florida. After that, he worked for the university as a specialist in
orthopedic transplants. With a partner, Jamie Grooms, he started a
company within the university specializing in spinal fusion, one of the
most common of orthopedic procedures.
In 1995, the two “spun out” the company from the university, calling it
University of Florida Tissue Bank. That year the company had $1 million in
revenues, with only six employees. Five years later, when the firm went
public, it had 550 employees and annual revenues of $120 million.
“More importantly, (we were) producing regenerative medicine solutions
for patients all across the United States on the scale of hundreds of
thousands of implants, and better implants, a year,” Dr. Mills explained.
“It was during that time that I really learned a lesson. And the key lesson
is: if you take care of patients, then your business is going to follow. If you
don’t take care of the patients, there is nothing you can do in order to get
your business to come along.”
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Randy Mills (Osiris photo)
Key achievements at Osiris
In 2004, at the age of 32, Dr. Mills was recruited to become the president
and CEO of Osiris Therapeutics, Inc., a Columbia, Md.-based company
that commercialized the world’s first stem cell product, Osteocel, for bone
regeneration. According to Mills, that product has brought a total of $1.5
billion in revenue to Osiris.
Under his leadership, in May 2012 Osiris received approval to market the
world’s first systemically infused stem cell drug, Prochymal, which it
developed to combat pediatric acute graft-versus-host disease. (It was
approved in Canada but is also available in the U.S.; click here to read
more.)
This condition occurs in patients receiving bone marrow transplants that
reject the person and attack the body.
“Patients will literally peel out of their skin,” Dr. Mills said, describing the
horrors of the condition. Patients with the condition have a life expectancy
of only 87 days, he added.
With Prochymal, patients got better two-thirds of the time, he said.
Dr. Mills attributed Osiris’s success to its intense focus on patients.
“The board room is covered with pictures of our patients,” he said.
“That’s my mission with CIRM,” he continued. “We’re going to focus on
the patients, and everything else is going to come along. If you get a sense
of urgency from me, it’s because, if a life expectancy of a disease is 87 days,
missing a month or two months or three months are actually real patients
dying.”
Putting criticisms of CIRM in perspective
The stem cell board’s selection of a new CEO with long experience in the
curehd.blogspot.com/2014/06/new-california-stem-cell-chief-stresses.html
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drug industry takes place a decade after California voters created CIRM by
approving Proposition 71, the California Stem Cell Research and Cures Act.
According to CIRM’s statistics, so far four clinical trials directly funded by
the organization have taken place – including an observational study of
Huntington’s disease patients at the University of California, Davis, the
basis for a potential CIRM-supported treatment trial envisioned by Dr.
Vicki Wheelock and Dr. Jan Nolta (click here to read more).
Six additional trials for different conditions are based on “discoveries
made by our grantees when they were carrying out CIRM-funded
research,” CIRM reports (click here to read more).
According to Kevin McCormack, CIRM’s senior director for public
communications and patient advocate outreach, five more directly funded
trials for various diseases will start by the end of 2014.
CIRM’s efforts have not yet produced a drug, although one or more
treatments could arise from the clinical trials.
Some in California have criticized CIRM’s performance. The San Francisco
Chronicle, for instance, editorialized that CIRM “hasn’t lived up to its
hype” and has compiled a “decidedly mixed” record, although it recognized
that California voters had “outsize expectations when they passed Prop.
71.”
The Chronicle further noted that “it’s been a struggle to get the agency to
use the best organizational practices. In 2012, a blue-ribbon committee of
the National Academy of Sciences released a report after a yearlong review
that found conflicts of interest on the CIRM board that threatened to
‘undermine respect for its decisions.’ It also found significant flaws in the
agency’s grant-approval process.”
The editorial added: “Progress on stem cell research has been significant –
but it’s been the progress of the tortoise rather than the hare.”
In general, news coverage of CIRM has been sporadic. After all, news
outlets typically don’t report on the work of scientists in the trenches.
In this blog, I have provided frequent coverage of HD science as well as
related stem cell research. In my 15 years writing about HD science, I’ve
learned that scientific progress is slow by nature. It’s not just the CIRM
projects that take a long time to produce results.
From my standpoint, stem cell science has produced a “growing array of
possibilities” for treatments and the “potential for a new era in human
health,” as I noted after attending the 2013 World Stem Cell Summit (click
here to read more).
Producing treatments is also extremely expensive. According to Jim
Greenwood, president and CEO of the Biotechnology Industry Association,
which organized the Bio Convention, developing a new drug in the U.S.
costs an average of $1.2 billion. CIRM and/or its affiliated researchers will
need to partner with the pharmaceutical industry to bring treatments to
market.
In the HD community, we earnestly hope for stem cell treatments, but
we’re also aware that a “cocktail” of different approaches (like gene
therapy) will likely be needed to deal with the complexities of the disease.
We’re rooting for all the researchers to find keys to treatments.
Crucial experience with clinical trials
With the need to show results, it’s not surprising the CIRM board chose a
new CEO from the business world.
curehd.blogspot.com/2014/06/new-california-stem-cell-chief-stresses.html
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As noted by David Jensen, author of the blog California Stem Cell Report,
CIRM’s previous two presidents, Zach Hall, Ph.D., and Alan Trounson,
Ph.D., came from “largely academic and non-business backgrounds….
Decisions are likely to come faster under Mills.”
In his introduction of Dr. Mills at the San Diego meeting, CIRM board
chair Dr. Thomas said that the new CEO met the many qualifications
sought by the organization, including familiarity with the process of
running stem cell clinical trials and seeking approval of drugs from
governmental agencies.
“Very few people can say they’ve had more experience in clinical trials in
stem cells,” Dr. Thomas said. “Very few people can say they’ve had more
experience with the regulators, not just from the U.S., but from other
countries as well.”

Randy Mills (left) and CIRM board chair Jonathan Thomas (CIRM photo)
The board also sought someone familiar with CIRM. Dr. Mills has spent
the last five years as a reviewer of proposals made to CIRM by stem cell
researchers seeking funding. (Click here to read more.)
During the audience Q & A, one woman asked Dr. Mills what he would do
to make the grant review process more “transparent.”
Recognizing that the process wasn’t “perfect,” Dr. Mills nevertheless said
he believed it was “pretty good” and already “remarkably transparent,”
with world experts involved in the reviews. He reminded the audience that
no “divining rod” exists to pick perfect projects. He added that he will work
for quicker approval of worthy applications.
Keeping CIRM running
Jeanne Loring, Ph.D., a leading expert on stem cells and Parkinson’s
disease at The Scripps Research Institute in San Diego, wanted to know
how Dr. Mills would prioritize CIRM spending from now through 2017,
when the last of the agency’s grants will be made and the original CIRM
allocation of $3 billion might run out.
The agency still has about $600 million in uncommitted funds. In all, $1.5
billion of its $3 billion budget has yet to be spent, as many budgeted
projects remain in progress.
“Let’s be careful on speculating on when CIRM is going to run out of
money,” Dr. Mills said in response to Dr. Loring’s question. “That (2017)
curehd.blogspot.com/2014/06/new-california-stem-cell-chief-stresses.html
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would be the absolute earliest. This is an important thing for people to
understand: in order for that date to be true, things have gone incredibly
well. Everything we funded, 100 percent of it, has worked. If that ‘17 date
happens, I’m a happy guy, because we are rattling off diseases left and
right.”
Dr. Mills explained that CIRM does “milestone-based funding.”
“So we’ll fund your project, but if you don’t hit your milestone, if it’s not
working, we stop funding,” he continued. “That seems like a pretty good
idea. So the projections on these running out of money is assuming that
everything is going along. Everything’s going along, and we can’t get
California to say, ‘Let’s keep doing it’? In a more practical sense, we’re not
going to run out of money by then, and everything’s not going to work
perfect. My job is to run CIRM as efficiently as we possibly can to develop
treatments.”
According to spokesperson McCormack, the CIRM board can still redirect
funding from the $1.5 billion as yet unspent. If a project comes in under
budget, CIRM can also redirect savings to other projects, he added.
Some stem cell advocates such as Don Reed, who served on the executive
board for the Prop 71 campaign, are already advocating a second round of
CIRM funding to be requested from the state by way of another ballot
proposition to be put before the voters. (You can watch Reed, HD advocate
Judy Roberson, and children’s neurological disorders advocate Alex
Richmond speak about their experiences by clicking here.)
Dr. Thomas has also spoken publicly about seeking private sources of
funding for CIRM. In this vein, Dr. Mills’ experience in capital markets –
one of the sought-for qualities in a CEO noted by Dr. Thomas – could
prove helpful.
"California (undertook) a very important task in creating a funding stream
for stem cell research," Clinton, referring to CIRM, said during her Q & A
at the Bio Convention. "Other states have followed suit, when it looked as
though the federal government would not be doing that. States have a role
to play, but we need a national framework."
‘Our urgency for cures’
Huntington’s disease advocates participated in the “Meet the New CIRM
President” events in San Diego as well as Los Angeles and San Francisco.
One of those participants, veteran advocate Frances Saldaña of Orange
County, sees Dr. Mills’ appointment as a positive step.
“I really liked Randy Mills,” Saldaña, a mother of three children stricken
with juvenile HD, told me in an e-mail about her encounter with Dr. Mills
at the June 10 Los Angeles meeting. “I feel that he really understands our
urgency to find cures.”
Saldaña’s daughter Margie Hayes – who became one of the very first HD
patients to advocate for CIRM support for Huntington’s stem cell research
when she spoke at a December 2007 CIRM board meeting – succumbed to
the disease on February 7. Hayes had just turned 44. She is survived by her
husband Craig and two teenaged children.
Saldaña’s husband also died of HD, which has afflicted several other
members of her extended family. She was recently presented the 2014
Living Our Values Award by Michael Drake, the chancellor of the
University of California, Irvine (UCI), for her work in HD community
service. Saldaña is the founder of HD-CARE, an Orange County care
organization affiliated with UCI’s Institute for Memory Impairments and
Neurological Disorders.
curehd.blogspot.com/2014/06/new-california-stem-cell-chief-stresses.html
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Saldaña said of Dr. Mills: “In the case of HD families, he completely
understands that we're in a race against time, as our families are dying.”

As mother Frances Saldaña (left) looks on, Margie Hayes tells about her
struggle against HD at the CIRM Spotlight on Huntington's Disease, Los
Angeles, December 12, 2007 (photo by Gene Veritas).
Posted by Gene Veritas at 6:28 PM
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